Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | brimonidine (Mirvaso®) | ||
| Formulation | 3 mg/g gel | ||
| Reference number | 2168 | ||
| Indication | Symptomatic treatment of facial erythema of rosacea in adult patients |
||
| Company | Galderma (UK) Ltd | ||
| BNF chapter | Skin | ||
| Assessment type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 2015 | ||
| NMG meeting date | 10/06/2015 | ||
| AWMSG meeting date | 15/07/2015 | ||
| Ratification by Welsh Government | 27/08/2015 | ||
| Date of issue | 02/09/2015 | ||
| Date of last review | 21/03/2019 | ||